What has ACE done for you lately? Here’s what we’ve been working on.
World Autoimmune Arthritis Day
Hosted by the International Foundation for Autoimmune Arthritis, the World Autoimmune Arthritis Day united dozen of nonprofits, advocates, and experts from around the world to provide educational and awareness information to patients, their supporters, and the general public. ACE participated in this virtual global race and expanded the arthritis conversation online. Continue reading →
Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis approved in Quebec.
As of June 1st, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Quebec’s drug formulary. Click here to view the detailed medication criteria.
Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.
Click here to view the most up-to-date version of ACE’s Report Card on provincial formulary reimbursement listings for biologic response modifiers.
Osteoporosis is a disease characterized by low bone mass and deterioration of bone quality. This results in bones becoming thin and weak, which increases the risk of fracture as they are easy to break. It is known as the “silent thief” because bone loss occurs without any symptoms. In fact, often it is not until someone fractures a wrist, spine, rib, or hip that osteoporosis is suspected (and often it is missed even after a fragility fracture).
As many as two million Canadians have osteoporosis. One in four women, including a third of women aged 60-70 years and two thirds of women aged 80 years and older, will be diagnosed with osteoporosis.
Research shows that weight-bearing exercise, including soccer, is an effective way to reduce the amount of bone loss over time and preserve bone mass, and thus, reduce your likelihood of developing osteoporosis and having a fracture. To prepare for the FIF Women’s World Cup™ this weekend and Father’s Day, #TeamArthritis challenges you to do something that reduce your chance of getting osteoporosis.
FIFA 11+ : Preventing osteoarthritis by preventing injuries in youth
The FIFA Women’s World Cup™ is here in Canada and causing excitement across the country. Our youth will see the best female soccer players in the world take their places on the field to play the “beautiful” game. Soccer in Canada has one of the largest participation rates in youth. However, there is a downside – injury – especially of the knee and ankle. Knee and ankle injury rate in soccer are significant for both boys and girls, with girls up to 8 times more likely to have an injury. Injuries cause pain and disability and can lead to long-term consequences – osteoarthritis (OA). Sports injuries are one of the leading causes of developing osteoarthritis later in life which results in daily pain and suffering for millions of people across Canada. Many people with OA can remember the injury that started their knee or ankle problems. Continue reading →
ACE launches second annual Canada’s Best Workplaces for Employees Living with Arthritis program
Canadian employers, working with their private health insurers, are increasingly looking for ways to promote patient-focused prevention, treatment and management of arthritis as part of a health and wellness program for employees. To recognize these best arthritis practices, Arthritis Consumer Experts (ACE) announces the second annual search for Canada’s Best Workplaces for Employees Living with Arthritis.
Categorizing companies by size (small, medium and large), ACE analyzes company practices and programs compared to other candidate companies based on criteria such as arthritis literacy, physical workplace adaptability, flexible hours and extended health benefit plans.
To determine if your company is eligible for Canada’s Best Workplaces for Employees Living with Arthritis program, please visit: jointhealth.org.
Subsequent entry biologics (SEBs) are a “hot topic” in health care today. They are a new class of medications entering the Canadian marketplace and consumers and patients living with autoimmune forms of arthritis and other diseases affecting the immune system need to learn about them from credible sources.
Arthritis Consumer Experts and the JointHealth™ family of education programs is pleased to offer you the latest facts on SEBs from leading patient educator and advocate:
Ms. Cheryl Koehn
Founder and President, Arthritis Consumer Experts
To register for the “SEB Facts” webinar, please complete the form. Please complete all fields marked * and click “submit”.
You will receive 2 reminder emails as the broadcast date nears.
Thank you for registering for Arthritis Consumer Experts’ “SEB facts” Webinar.